Dr. Joan Fallon, Founder and CEO of Curemark, is leading the charge against some of the world’s most complex medical challenges. A scientist, pediatric specialist, and award-winning entrepreneur, she has devoted her career to transforming children’s health. Dr. Fallons discusses the groundbreaking discovery linking an enzyme deficiency to autism sparked the creation of CM-AT, Curemark’s lead drug, now in Phase III clinical trials with FDA Fast Track status. Dr. Fallon discusses the critical gaps in treatment for autism and other neurological disorders, and how Curemark’s bold, science driven approach is redefining what’s possible in medicine.